XBIOXenetic Biosciences, Inc.
- AccessWire
Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform
Expanded collaborative research initiatives reinforce the Company's long-term DNase development strategyOngoing generation of translational data designed to support future clinical development and deepen ...
- AccessWire
Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma
Company evaluating systemic recombinant human DNase I in combination with anti-CD19 CAR T cells targeting lymphoma patients in stable or progressive disease at lymphodepletion Company reported strong positive preclinical ...
- AccessWire
Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival
New preclinical and translational findings position DNase I as a potentially transformative adjunct therapy for CAR-T treatment in aggressive B cell malignanciesData highlight potential of DNase I to improve CAR-T cell ...
- AccessWire
Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform
Advancements across investigator-initiated studies, translational research and manufacturing activities supporting future clinical developmentStrengthened financial profile with continued royalty revenue growthEnded ...
- AccessWire
Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting
FRAMINGHAM, MA / ACCESS Newswire / April 22, 2026 / Xenetic Biosciences, Inc. , a biopharmaceutical company focused on advancing innovative immuno-oncology technologies ...
- AccessWire
Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results
Encouraging preclinical and translational data supporting DNase-based approaches to target NETs in difficult-to-treat cancersStrategic focus on investigator-initiated exploratory studies and institutional ...
- AccessWire
Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting
Adjourns 2025 Annual Meeting of StockholdersUrges Stockholders Who Have Not Voted To Get Votes In FRAMINGHAM, MA / ACCESS Newswire / December 11, 2025 / Xenetic Biosciences, Inc. ("Xenetic" or the ...
- AccessWire
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform
FRAMINGHAM, MA / ACCESS Newswire / November 19, 2025 / Xenetic Biosciences, Inc. , a biopharmaceutical company focused on advancing innovative immuno-oncology ...
- AccessWire
Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results
Continued execution on collaborations and exploratory investigator-initiated studies with institutional partnersSecured net proceeds of approximately $3.9 million from October 2025 offering FRAMINGHAM, MA / ACCESS ...
- SEC
8-K Form - Current report, items 1.01, 8.01, and 9.01 - Xenetic Biosciences, Inc. (0001534525) (Filer)
Current report, items 1.01, 8.01, and 9.01 ...
- AccessWire
Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock
FRAMINGHAM, MA / ACCESS Newswire / October 10, 2025 / Xenetic Biosciences, Inc. , a biopharmaceutical company focused on advancing innovative immuno-oncology ...
- SEC
424B5 Form - Prospectus [Rule 424(b)(5)] - Xenetic Biosciences, Inc. (0001534525) (Filer)
Prospectus [Rule 424(b)(5)] ...
- AccessWire
Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results
Expanded strategic partnership with The Scripps Research Institute to advance proof-of-concept studies and further develop its program combining systemic DNase I with CAR T-cell therapiesEnded the quarter with $4.8 ...
- AccessWire
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma
Investigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv Sourasky Medical Center FRAMINGHAM, MA / ACCESS Newswire / July 30, 2025 / Xenetic Biosciences, Inc. ...
- AccessWire
Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Research and development collaboration program to include additional models of lymphoma and leukemia to further validate DNase-I data demonstrated to date FRAMINGHAM, MA / ACCESS Newswire / July 23, 2025 / Xenetic ...
- SEC
8-K Form - Current report, items 2.02 and 9.01 - Xenetic Biosciences, Inc. (0001534525) (Filer)
Current report, items 2.02 and 9.01 ...
- AccessWire
Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
Strategic focus on exploratory investigator-initiated clinical studies with institutional partnersContinued progress of DNase I development program towards IND and first-in-human study for treatment of pancreatic ...
- SEC
10-Q Form - Quarterly report [Sections 13 or 15(d)] - Xenetic Biosciences, Inc. (0001534525) (Filer)
Quarterly report [Sections 13 or 15(d)] ...
- SEC
10-K/A Form - [Amend] Annual report [Section 13 and 15(d), not S-K Item 405] - Xenetic Biosciences, Inc. (0001534525) (Filer)
[Amend] Annual report [Section 13 and 15(d), not S-K Item 405] ...
- SEC
10-K/A Form - [Amend] Annual report [Section 13 and 15(d), not S-K Item 405] - Xenetic Biosciences, Inc. (0001534525) (Filer)
[Amend] Annual report [Section 13 and 15(d), not S-K Item 405] ...
- SEC
8-K Form - Current report, items 4.01 and 9.01 - Xenetic Biosciences, Inc. (0001534525) (Filer)
Current report, items 4.01 and 9.01 ...
- Analyst Upgrades
HC Wainwright & Co. Reiterates Neutral on Xenetic Biosciencesto Neutral
HC Wainwright & Co. analyst Joseph Pantginis reiterates Xenetic Biosciences from Neutral to Neutral. ...
- AccessWire
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
- Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the Society for Immunotherapy of Cancer Spring ...
- AccessWire
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma
Investigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv Sourasky Medical Center FRAMINGHAM, MA / ACCESS Newswire / March 26, 2025 / Xenetic Biosciences, Inc. ...
- Analyst Upgrades
HC Wainwright & Co. Reiterates Neutral on Xenetic Biosciencesto Neutral
HC Wainwright & Co. analyst Joseph Pantginis reiterates Xenetic Biosciences from Neutral to Neutral. ...